Serum anti‑KIAA0513 antibody as a common biomarker for mortal atherosclerotic and cancerous diseases

Hiwasa,Takaki; Yoshida,Yoichi; Kubota,Masaaki; Li,Shu-Yang; Zhang,Bo-Shi; Matsutani,Tomoo; Mine,Seiichiro; Machida,Toshio; Ito,Masaaki; Yajima,Satoshi; Shirouzu,Mikako; Yokoyama,Shigeyuki; Sata,Mizuki; Yamagishi,Kazumasa; Iso,Hiroyasu; Sawada,Norie; Tsugane,Shoichiro; Takemoto,Minoru; Hayashi,Aiko; Yokote,Koutaro; Kobayashi,Yoshio; Matsushita,Kazuyuki; Tatsumi,Koichiro; Takizawa,Hirotaka; Tomiyoshi,Go; Shimada,Hideaki; Higuchi,Yoshinori

doi:10.3892/mi.2024.169

Serum anti‑KIAA0513 antibody as a common biomarker for mortal atherosclerotic and cancerous diseases

Authors:
- Takaki Hiwasa
- Yoichi Yoshida
- Masaaki Kubota
- Shu-Yang Li
- Bo-Shi Zhang
- Tomoo Matsutani
- Seiichiro Mine
- Toshio Machida
- Masaaki Ito
- Satoshi Yajima
- Mikako Shirouzu
- Shigeyuki Yokoyama
- Mizuki Sata
- Kazumasa Yamagishi
- Hiroyasu Iso
- Norie Sawada
- Shoichiro Tsugane
- Minoru Takemoto
- Aiko Hayashi
- Koutaro Yokote
- Yoshio Kobayashi
- Kazuyuki Matsushita
- Koichiro Tatsumi
- Hirotaka Takizawa
- Go Tomiyoshi
- Hideaki Shimada
- Yoshinori Higuchi
View Affiliations

Affiliations: Department of Neurological Surgery, Graduate School of Medicine, Chiba University, Chiba 260‑8670, Japan, Department of Gastroenterological Surgery and Clinical Oncology, Toho University Graduate School of Medicine, Tokyo 143‑8541, Japan, Laboratory for Protein Functional and Structural Biology, RIKEN Center for Biosystems Dynamics Research, Yokohama, Kanagawa 230‑0045, Japan, RIKEN Structural Biology Laboratory, Yokohama, Kanagawa 230‑0045, Japan, Department of Public Health Medicine, Faculty of Medicine, and Health Services Research and Development Center, University of Tsukuba, Tsukuba 305‑8575, Japan, Public Health, Department of Social Medicine, Osaka University Graduate School of Medicine, Suita, Osaka 565‑0871, Japan, Epidemiology and Prevention Group, Center for Public Health Sciences, National Cancer Center, Tokyo 104‑0045, Japan, Department of Endocrinology, Hematology and Gerontology, Graduate School of Medicine, Chiba University, Chiba 260‑8670, Japan, Department of Cardiovascular Medicine, Graduate School of Medicine, Chiba University, Chiba 260‑8670, Japan, Department of Laboratory Medicine & Division of Clinical Genetics, Chiba University Hospital, Chiba 260‑8677, Japan, Department of Respirology, Graduate School of Medicine, Chiba University, Chiba 260‑8670, Japan, Port Square Kashiwado Clinic, Kashiwado Memorial Foundation, Chiba 260‑0025, Japan, Medical Project Division, Research Development Center, Fujikura Kasei Co., Saitama 340‑0203, Japan, Department of Clinical Oncology, Toho University Graduate School of Medicine, Tokyo 143‑8541, Japan
Published online on: June 19, 2024 https://doi.org/10.3892/mi.2024.169
Article Number: 45
Copyright : © Hiwasa et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Numerous antibody biomarkers have been reported for cancer and atherosclerosis‑related diseases. The major complications of atherosclerosis and diabetes mellitus (DM) are acute ischemic stroke (AIS), cardiovascular disease (CVD) and chronic kidney disease (CKD). Cancer development is accompanied by arterial disorders, such as angiogenesis and atherosclerosis, and DM is a risk factor for the development of certain types of cancer. Atherosclerosis‑related diseases and cancers are therefore interrelated and could be detected using a common biomarker. In the present study, the initial screening using the protein array method identified KIAA0513 as an antigen recognized by serum IgG antibodies in patients with atherosclerosis. The amplified luminescent proximity homogeneous assay‑linked immunosorbent assay revealed significantly higher serum antibody levels against recombinant KIAA0513 protein in patients with AIS, transient ischemic attack (TIA), DM, CVD, obstructive sleep apnea syndrome (OSAS), CKD and solid cancers, such as esophageal, gastric, colon, lung and breast cancers, compared with healthy donors. A receiver operating characteristic (ROC) analysis revealed that the highest areas under the ROC curves of anti‑KIAA0513 antibodies were obtained for esophageal cancer, nephrosclerosis‑type CKD and DM. Spearman's correlation analysis revealed that serum anti‑KIAA0513 antibody levels were associated with maximum intima‑media thickness and plaque score, which are indices of atherosclerosis and stenosis. Serum anti‑KIAA0513 antibody markers appear to be useful for diagnosing AIS, TIA, DM, CVD, OSAS, CKD and solid cancers, and may reflect common arterial alterations leading to atherosclerotic and cancerous diseases.

View Figures

View References

1	Goo YA and Goodlett DR: Advances in proteomic prostate cancer biomarker discovery. J Proteomics. 73:1839–1850. 2010.PubMed/NCBI View Article : Google Scholar
2	Imafuku Y, Omenn GS and Hanash S: Proteomics approaches to identify tumor antigen directed autoantibodies as cancer biomarkers. Dis Markers. 20:149–153. 2004.PubMed/NCBI View Article : Google Scholar
3	Ho PTB, Clark IM and Le LTT: MicroRNA-based diagnosis and therapy. Int J Mol Sci. 23(7167)2022.PubMed/NCBI View Article : Google Scholar
4	Kramer J, Harcos P, Prohászka Z, Horváth L, Karádi I, Singh M, Császár A, Romics L and Füst G: Frequencies of certain complement protein alleles and serum levels of anti-heat-shock protein antibodies in cerebrovascular diseases. Stroke. 31:2648–2652. 2000.PubMed/NCBI View Article : Google Scholar
5	Machida T, Kubota M, Kobayashi E, Iwadate Y, Saeki N, Yamaura A, Nomura F, Takiguchi M and Hiwasa T: Identification of stroke-associated-antigens via screening of recombinant proteins from the human expression cDNA library (SEREX). J Translat Med. 13(71)2015.PubMed/NCBI View Article : Google Scholar
6	Yoshida Y, Wang H, Hiwasa T, Machida T, Kobayashi E, Mine S, Tomiyoshi G, Nakamura R, Shinmen N, Kuroda H, et al: Elevation of autoantibody level against PDCD11 in patients with transient ischemic attack. Oncotarget. 9:8836–8848. 2017.PubMed/NCBI View Article : Google Scholar
7	Wang H, Zhang XM, Tomiyoshi G, Nakamura R, Shinmen N, Kuroda H, Kimura R, Mine S, Kamitsukasa I, Wada T, et al: Association of serum levels of antibodies against MMP1, CBX1, and CBX5 with transient ischemic attack and cerebral infarction. Oncotarget. 9:5600–5613. 2017.PubMed/NCBI View Article : Google Scholar
8	Yoshida Y, Zhang XM, Wang H, Machida T, Mine S, Kobayashi E, Adachi A, Matsutani T, Kamitsukasa I, Wada T, et al: Elevated levels of autoantibodies against DNAJC2 in sera of patients with atherosclerotic diseases. Heliyon. 6(e04661)2020.PubMed/NCBI View Article : Google Scholar
9	Li SY, Yoshida Y, Kobayashi E, Kubota M, Matsutani T, Mine S, Machida T, Maezawa Y, Takemoto M, Yokote K, et al: Serum anti-AP3D1 antibodies are risk factors for acute ischemic stroke related with atherosclerosis. Sci Rep. 11(13450)2021.PubMed/NCBI View Article : Google Scholar
10	Kubota M, Yoshida Y, Kobayashi E, Matsutani T, Li SY, Zhang BS, Mine S, Machida T, Takizawa H, Hiwasa T and Iwadate Y: Serum anti-SERPINE1 antibody as a potential biomarker of acute cerebral infarction. Sci Rep. 11(21772)2021.PubMed/NCBI View Article : Google Scholar
11	Hiwasa T, Wang H, Goto KI, Mine S, Machida T, Kobayashi E, Yoshida Y, Adachi A, Matsutani T, Sata M, et al: Serum anti-DIDO1, anti-CPSF2, and anti-FOXJ2 antibodies as predictive risk markers for acute ischemic stroke. BMC Med. 19(131)2021.PubMed/NCBI View Article : Google Scholar
12	Kubota M, Zhang BS, Li SY, Yoshida Y, Wang H, Adachi A, Matsutani T, Mine S, Machida T, Kamitsukasa I, et al: Serum anti-TSTD2 antibody as a biomarker for atherosclerosis-induced ischemic stroke and chronic kidney disease. Med Int (Lond). 3(4)2022.PubMed/NCBI View Article : Google Scholar
13	Hiwasa T, Machida T, Zhang XM, Kimura R, Wang H, Iwase K, Ashino H, Taira A, Arita E, Mine S, et al: Elevated levels of autoantibodies against ATP2B4 and BMP-1 in sera of patients with atherosclerosis-related diseases. Immunome Res. 11(097)2015.
14	Nakamura R, Tomiyoshi G, Shinmen N, Kuroda H, Kudo T, Doi H, Mine S, Machida T, Kamitsukasa I, Wada T, et al: An anti-deoxyhypusine synthase antibody as a marker of atherosclerosis-related cerebral infarction, myocardial infarction, diabetes mellitus, and chronic kidney disease. SM Atheroscler J. 1(1001)2017.
15	Hiwasa T, Tomiyoshi G, Nakamura R, Shinmen N, Kuroda H, Kunimatsu M, Mine S, Machida T, Sato E, Takemoto M, et al: Serum SH3BP5-specific antibody level is a biomarker of atherosclerosis. Immunome Res. 13(132)2017.
16	Zhang XM, Wang H, Mine S, Takemoto M, Yokote K, Kitamura K, Kobayashi Y, Machida T, Kobayashi E, Yoshida Y, et al: Association of serum anti-prolylcarboxypeptidase antibody marker with atherosclerotic diseases accompanied by hypertension. J Mol Biomark Diagn. 8(361)2017.
17	Sumazaki M, Shimada H, Ito M, Shiratori F, Kobayashi E, Yoshida Y, Adachi A, Matsutani T, Iwadate Y, Mine S, et al: Serum anti-LRPAP1 is a common biomarker for digestive organ cancers and atherosclerotic diseases. Cancer Sci. 111:4453–4464. 2020.PubMed/NCBI View Article : Google Scholar
18	Li SY, Yoshida Y, Kobayashi E, Adachi A, Hirono S, Matsutani T, Mine S, Machida T, Ohno M, Nishi E, et al: Association between serum anti-ASXL2 antibody levels and acute ischemic stroke, acute myocardial infarction, diabetes mellitus, chronic kidney disease and digestive organ cancer, and their possible association with atherosclerosis and hypertension. Int J Mol Med. 46:1274–1288. 2020.PubMed/NCBI View Article : Google Scholar
19	Chen PM, Ohno M, Hiwasa T, Nishi K, Saijo S, Sakamoto J, Morita Y, Matsuda S, Watanabe S, Kuwabara Y, et al: Nardilysin is a promising biomarker for the early diagnosis of acute coronary syndrome. Int J Cardiol. 243:1–8. 2017.PubMed/NCBI View Article : Google Scholar
20	Palmer JP, Asplin CM, Clemons P, Lyen K, Tatpati O, Raghu PK and Paquette TL: Insulin antibodies in insulin-dependent diabetics before insulin treatment. Science. 222:1337–1339. 1983.PubMed/NCBI View Article : Google Scholar
21	Baekkeskov S, Aanstoot HJ, Christgau S, Reetz A, Solimena M, Cascalho M, Folli F, Richter-Olesen H and De Camilli P: Identification of the 64K autoantigen in insulin dependent diabetes as the GABA-synthesizing enzyme glutamic acid decarboxylase. Nature. 347:151–156. 1990.PubMed/NCBI View Article : Google Scholar
22	Hiwasa T, Zhang XM, Kimura R, Ohno M, Chen PM, Nishi E, Ono K, Kimura T, Kamitsukasa I, Wada T, et al: Elevated adiponectin antibody levels in sera of patients with atherosclerosis-related coronary artery disease, cerebral infarction, and diabetes mellitus. J Circ Biomark. 5(8)2016.PubMed/NCBI View Article : Google Scholar
23	Sugimoto K, Tomiyoshi G, Mori M, Kuwabara S, Hirano S, Sawai S, Beppu M, Muto M, Uzawa A, Kitamura K, et al: Identification of serum anti-GADD34 antibody as a common marker of diabetes mellitus and parkinson disease. J Alzheimers Dis Parkinsonism. 7(358)2017.
24	Tomiyoshi G, Nakamura R, Shinmen N, Yoshida Y, Mine S, Machida T, Iwase K, Iwadate Y, Hiwasa T and Kuroda H: GADD34 activates p53 and may have utility as a marker of atherosclerosis. Front Med (Lausanne). 10(1128921)2023.PubMed/NCBI View Article : Google Scholar
25	Yamagata H, Hayashi A, Yoshida Y, Koshizaka M, Onishi S, Yoshida T, Hiwasa T and Takemoto M: Association of high proprotein convertase subtilisin/kexin type 9 antibody level with poor prognosis in patients with diabetes: A prospective study. Sci Rep. 13(5391)2023.PubMed/NCBI View Article : Google Scholar
26	Shimada H, Takeda A, Arima M, Okazumi S, Matsubara H, Nabeya Y, Funami Y, Hayashi H, Gunji Y, Suzuki T, et al: Serum p53 antibody is a useful tumor marker in superficial esophageal squamous cell carcinoma. Cancer. 89:1677–1683. 2000.PubMed/NCBI
27	Shimada H, Ochiai T and Nomura F: Japan p53 Antibody Research Group. Titration of serum p53 antibodies in 1,085 patients with various types of malignant tumors: A multiinstitutional analysis by the Japan p53 antibody research group. Cancer. 97:682–689. 2003.PubMed/NCBI View Article : Google Scholar
28	Nakashima K, Shimada H, Ochiai T, Kuboshima M, Kuroiwa N, Okazumi S, Matsubara H, Nomura F, Takiguchi M and Hiwasa T: Serological identification of TROP2 by recombinant cDNA expression cloning using sera of patients with esophageal squamous cell carcinoma. Int J Cancer. 112:1029–1035. 2004.PubMed/NCBI View Article : Google Scholar
29	Kuboshima M, Shimada H, Liu TL, Nakashima K, Nomura F, Takiguchi M, Hiwasa T and Ochiai T: Identification of a novel SEREX antigen, SLC2A1/GLUT1, in esophageal squamous cell carcinoma. Int J Oncol. 28:463–468. 2006.PubMed/NCBI
30	Kuboshima M, Shimada H, Liu TL, Nomura F, Takiguchi M, Hiwasa T and Ochiai T: Presence of serum tripartite motif-containing 21 antibodies in patients with esophageal squamous cell carcinoma. Cancer Sci. 97:380–386. 2006.PubMed/NCBI View Article : Google Scholar
31	Shimada H, Kuboshima M, Shiratori T, Nabeya Y, Takeuchi A, Takagi H, Nomura F, Takiguchi M, Ochiai T and Hiwasa T: Serum anti-myomegalin antibodies in patients with esophageal squamous cell carcinoma. Int J Oncol. 30:97–103. 2007.PubMed/NCBI
32	Shimada H, Shiratori T, Yasuraok M, Kagaya A, Kuboshima M, Nomura F, Takiguchi M, Ochiai T, Matsubara H and Hiwasa T: Identification of makorin 1 as a novel SEREX antigen of esophageal squamous cell carcinoma. BMC Cancer. 9(232)2009.PubMed/NCBI View Article : Google Scholar
33	Kagaya A, Shimada H, Shiratori T, Kuboshima M, Nakashima-Fujita K, Yasuraoka M, Nishimori T, Kurei S, Hachiya T, Murakami A, et al: Identification of a novel SEREX antigen family, ECSA, in esophageal squamous cell carcinoma. Proteome Sci. 9(31)2011.PubMed/NCBI View Article : Google Scholar
34	Shimada H, Ito M, Kagaya A, Shiratori T, Kuboshima M, Suzuki M, Liu TL, Nabeya Y, Matsubara H, Matsushita K, et al: Elevated serum antibody levels against cyclin L2 in patients with esophageal squamous cell carcinoma. J Cancer Sci Ther. 7:60–66. 2015.
35	Ito M, Hiwasa T, Yajima S, Suzuki T, Oshima Y, Nanami T, Sumazaki M, Shiratori F, Li SY, Iwadate Y, et al: Low anti-CFL1 antibody with high anti-ACTB antibody is a poor prognostic factor in esophageal squamous cell carcinoma. Esophagus. 19:617–625. 2022.PubMed/NCBI View Article : Google Scholar
36	Ito M, Yajima S, Suzuki T, Oshima Y, Nanami T, Sumazaki M, Shiratori F, Wang H, Hu L, Takizawa H, et al: The combination of positive anti-WDR1 antibodies with negative anti-CFL1 antibodies is a poor prognostic factor for patients with esophageal carcinoma. Med Int (Lond). 3(11)2023.PubMed/NCBI View Article : Google Scholar
37	Kobayashi S, Hoshino T, Hiwasa T, Satoh M, Rahmutulla B, Tsuchida S, Komukai Y, Tanaka T, Matsubara H, Shimada H, et al: Anti-FIRs (PUF60) auto-antibodies are detected in the sera of early-stage colon cancer patients. Oncotarget. 7:82493–82503. 2016.PubMed/NCBI View Article : Google Scholar
38	Kobayashi S, Hiwasa T, Ishige T, Rahmutulla B, Kano M, Hoshino T, Minamoto T, Shimada H, Nomura F, Matsubara H and Matsushita K: Anti-FIRΔexon2, a splicing variant form of PUF60, auto-antibody is detected in the sera of esophageal squamous cell carcinoma. Cancer Sci. 110:2004–2013. 2019.PubMed/NCBI View Article : Google Scholar
39	Matsutani T, Hiwasa T, Takiguchi M, Oide T, Kunimatsu M, Saeki N and Iwadate Y: Autologous antibody to src-homology 3-domain GRB2-like 1 specifically increases in the sera of patients with low-grade gliomas. J Exp Clin Cancer Res. 31(85)2012.PubMed/NCBI View Article : Google Scholar
40	Adachi-Hayama M, Adachi A, Shinozaki N, Matsutani T, Hiwasa T, Takiguchi M, Saeki N and Iwadate Y: Circulating anti-filamin C antibody as a potential serum biomarker for low-grade gliomas. BMC Cancer. 14(452)2014.PubMed/NCBI View Article : Google Scholar
41	Hontani K, Tsuchikawa T, Hiwasa T, Nakamura T, Ueno T, Kushibiki T, Takahashi M, Inoko K, Takano H, Takeuchi S, et al: Identification of novel serum autoantibodies against EID3 in non-functional pancreatic neuroendocrine tumors. Oncotarget. 8:106206–106221. 2017.PubMed/NCBI View Article : Google Scholar
42	Takahashi M, Tsuchikawa T, Hiwasa T, Nakamura T, Hontani K, Kushibiki T, Inoko K, Takano H, Hatanaka Y, Matsushita K, et al: Identification of antibody against wingless-type MMTV integration site family member 7B as a biliary cancer tumor marker. Oncol Rep. 49(34)2023.PubMed/NCBI View Article : Google Scholar
43	Matsumura T, Terada J, Kinoshita T, Sakurai Y, Yahaba M, Ema R, Amata A, Sakao S, Nagashima K, Tatsumi K and Hiwasa T: Circulating anti-coatomer protein complex subunit epsilon (COPE) autoantibodies as a potential biomarker for cardio- and cerebro-vascular events in patients with obstructive sleep apnea. J Clin Sleep Med. 13:393–400. 2017.PubMed/NCBI View Article : Google Scholar
44	Matsumura T, Terada J, Kinoshita T, Sakurai Y, Yahaba M, Tsushima K, Sakao S, Nagashima K, Iwata Y, Ozaki T, et al: Autoantibody against NBL1 in obstructive sleep apnea patients with cardiovascular disease. PLoS One. 13(e0195015)2018.PubMed/NCBI View Article : Google Scholar
45	Katsumata Y, Terada J, Matsumura T, Koshikawa K, Sakao S, Tomiyoshi G, Shinmen N, Nakamura R, Kuroda H, Nagashima K, et al: Circulating anti-sorting nexins 16 antibodies as an emerging biomarker of coronary artery disease in patients with obstructive sleep apnea. Diagnostics (Basel). 10(71)2020.PubMed/NCBI View Article : Google Scholar
46	Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL and Marsh EE III: Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in acute stroke treatment. Stroke. 24:35–41. 1993.PubMed/NCBI View Article : Google Scholar
47	Nishiura R, Fujimoto S, Sato Y, Yamada K, Hisanaga S, Hara S, Nakao H and Kitamura K: Elevated osteoprotegerin levels predict cardiovascular events in new hemodialysis patients. Am J Nephrol. 29:257–263. 2009.PubMed/NCBI View Article : Google Scholar
48	Komatsu H, Fujimoto S, Hara S, Fukuda A, Fukudome K, Yamada K, Sato Y and Kitamura K: Recent therapeutic strategies improve renal outcome in patients with IgA nephropathy. Am J Nephrol. 30:19–25. 2009.PubMed/NCBI View Article : Google Scholar
49	Chumpolkulwong N, Sakamoto K, Hayashi A, Iraha F, Shinya N, Matsuda N, Kiga D, Urushibata A, Shirouzu M, Oki K, et al: Translation of ‘rare’ codons in a cell-free protein synthesis system from escherichia coli. J Struct Funct Genomics. 7:31–36. 2006.PubMed/NCBI View Article : Google Scholar
50	Tsugane S and Sawada N: The JPHC study: Design and some findings on the typical Japanese diet. Jpn J Clin Oncol. 44:777–782. 2014.PubMed/NCBI View Article : Google Scholar
51	Ikeda A, Iso H, Sasazuki S, Inoue M and Tsugane S: JPHC Study Group. The combination of Helicobacter pylori- and cytotoxin-associated gene-A seropositivity in relation to the risk of myocardial infarction in middle-aged Japanese: The Japan public health center-based study. Atherosclerosis. 230:67–72. 2013.PubMed/NCBI View Article : Google Scholar
52	Iso H, Noda H, Ikeda A, Yamagishi K, Inoue M, Iwasaki M and Tsugane S: The impact of C-reactive protein on risk of stroke, stroke subtypes, and ischemic heart disease in middle-aged Japanese: The Japan public health center-based study. J Atheroscler Thromb. 19:756–766. 2012.PubMed/NCBI
53	Camp RL, Dolled-Filhart M and Rimm DL: X-tile: A new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 10:7252–7259. 2004.PubMed/NCBI View Article : Google Scholar
54	Lauriat TL, Dracheva S, Kremerskothen J, Duning K, Haroutunian V, Buxbaum JD, Hyde TM, Kleinman JE and McInnes LA: Characterization of KIAA0513, a novel signaling molecule that interacts with modulators of neuroplasticity, apoptosis, and the cytoskeleton. Brain Res. 1121:1–11. 2006.PubMed/NCBI View Article : Google Scholar
55	Tran LT, Park HJ and Kim HD: Is the carotid intima-media thickness really a good surrogate marker of atherosclerosis? J Atheroscler Thromb. 19:680–690. 2012.PubMed/NCBI View Article : Google Scholar
56	Zureik M, Ducimetière P, Touboul PJ, Courbon D, Bonithon-Kopp C, Berr C and Magne C: Common carotid intima-media thickness predicts occurrence of carotid atherosclerotic plaques: Longitudinal results from the aging vascular study (EVA) study. Arterioscler Thromb Vasc Biol. 20:1622–1629. 2000.PubMed/NCBI View Article : Google Scholar
57	Shirai K, Utino J, Otsuka K and Takata M: A novel blood pressure-independent arterial wall stiffness parameter; cardio-ankle vascular index (CAVI). J Atheroscler Thromb. 13:101–107. 2006.PubMed/NCBI View Article : Google Scholar
58	Floras JS: Hypertension and sleep apnea. Can J Cardiol. 31:889–897. 2015.PubMed/NCBI View Article : Google Scholar
59	Gallagher EJ and LeRoith D: Obesity and diabetes: The increased risk of cancer and cancer-related mortality. Physiol Rev. 95:727–748. 2015.PubMed/NCBI View Article : Google Scholar
60	Goto A, Yamaji T, Sawada N, Momozawa Y, Kamatani Y, Kubo M, Shimazu T, Inoue M, Noda M, Tsugane S and Iwasaki M: Diabetes and cancer risk: A mendelian randomization study. Int J Cancer. 146:712–719. 2020.PubMed/NCBI View Article : Google Scholar
61	Tapia-Vieyra JV, Delgado-Coello B and Mas-Oliva J: Atherosclerosis and cancer; A resemblance with far-reaching implications. Arch Med Res. 48:12–26. 2017.PubMed/NCBI View Article : Google Scholar
62	Makrilia N, Lappa T, Xyla V, Nikolaidis I and Syrigos K: The role of angiogenesis in solid tumours: An overview. Eur J Intern Med. 20:663–671. 2009.PubMed/NCBI View Article : Google Scholar
63	Jarvandi S, Davidson NO and Schootman M: Increased risk of colorectal cancer in type 2 diabetes is independent of diet quality. PLoS One. 8(e74616)2013.PubMed/NCBI View Article : Google Scholar
64	Fujihara S, Kato K, Morishita A, Iwama H, Nishioka T, Chiyo T, Nishiyama N, Miyoshi H, Kobayashi M, Kobara H, et al: Antidiabetic drug metformin inhibits esophageal adenocarcinoma cell proliferation in vitro and in vivo. Int J Oncol. 46:2172–2180. 2015.PubMed/NCBI View Article : Google Scholar
65	Berger NA: Young adult cancer: Influence of the obesity pandemic. Obesity (Silver Spring). 26:641–650. 2018.PubMed/NCBI View Article : Google Scholar
66	Hiwasa T and Shimada H: Autoantibody in cancer. In: Biomarkers in Cancer Therapy. Shimada H (ed). Springer Nature, Singapore, 25-40, 2018.
67	Zhou Y, Yang Q, Chi J, Dong B, Lv W, Shen L and Wang Y: Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: A systematic review and meta-analysis. Int J Infect Dis. 99:47–56. 2020.PubMed/NCBI View Article : Google Scholar
68	Wu T, Zuo Z, Kang S, Jiang L, Luo X, Xia Z, Liu J, Xiao X, Ye M and Deng M: Multi-organ dysfunction in patients with COVID-19: A systematic review and meta-analysis. Aging Dis. 11:874–894. 2020.PubMed/NCBI View Article : Google Scholar
69	Ye Q, Lu D, Shang S, Fu J, Gong F, Shu Q and Mao J: Crosstalk between coronavirus disease 2019 and cardiovascular disease and its treatment. ESC Heart Fail. 7:3464–3472. 2020.PubMed/NCBI View Article : Google Scholar
70	Maas MB, Kim M, Malkani RG, Abbott SM and Zee PC: Obstructive sleep apnea and risk of COVID-19 infection, hospitalization and respiratory failure. Sleep Breath. 25:1155–1157. 2021.PubMed/NCBI View Article : Google Scholar